Navigation Links
Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards
Date:9/29/2010

HOUSTON, Sept. 29 /PRNewswire/ -- The Gulf Coast Regional Center of Innovation and Commercialization (GCRCIC) is pleased to announce three companies who will receive up to a total of $2.9 million in commercialization awards from the Texas Emerging Technology Fund (TETF).  

(Logo:  http://photos.prnewswire.com/prnh/20090604/AQ28157LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090604/AQ28157LOGO)

The TETF program was established by Gov. Perry and the Texas Legislature in 2005 to attract the best scientists and researchers to Texas, increase high-paying jobs, and help start-up companies get off the ground faster.

"The ETF was created to strengthen our state's high tech economy by supporting promising cutting-edge technologies during the critical phase between earliest innovation and market viability," Gov. Perry said. "I applaud everyone involved in these worthy endeavors and look forward to the day when we can say the cure for drug resistant bacteria, a cost and life-saving treatment plan and a successful treatment for ovarian and possibly breast cancer were all developed to maturity here in Texas."

"These innovative companies are prominent examples of how the TETF supports Houston's transformation as a global hub of technology innovation and commercialization," said Walter Ulrich, president and CEO, Houston Technology Center.  "We are committed to accelerating the award winners to bring their technologies to Texas—and the world—as quickly as possible."

The latest TETF award recipients include these HTC client companies:

AuricX Pharmaceuticals, Inc., is a pharmaceutical development company based in Houston.  AuricX is focused on the development and commercialization of novel anti-infectives to treat infections arising from Staphylococcus aureus (S.aureus), Methicillin-resistant Staphylococcus aureus (MRSA) and other difficult to treat pathogens.  AuricX is commercializing a repurposed clinical trial stage drug which is being developed to treat S. Aureus infections.  AuricX was formed in 2006 and is managed by Chicago-based Wildcat Venture Management.  AuricX Pharmaceutical is being awarded $250,000 Pre-Seed Commercialization Award.

Blue Box Health, Inc. is a technology-enabled case management corporation focusing on early detection and mitigation of chronic disease decompensation. The business focus is on converting chronic disease decompensation emergencies to urgencies that are cared for in the normal course of business. Blue Box Health, Inc. has developed a remote biosensor for cardiac output, the Blue Scale, together with cloud-based analytics that will reduce overall costs of chronic disease management for hospitals and health providers while improve lifestyle and life expectancy of heart failure patients.  Blue Box Health, Inc. is being awarded $250,000 Pre-Seed Commercialization Award.

Oncolix, Inc. commenced operations in 2006 in South Carolina and relocated to Texas in 2009 and is focused on cancer. Their drug, Prolanta, has the potential to be the first non-chemotherapy drug approved for ovarian cancer and clinical trials will start early next year with strategic assistance from MD Anderson. Oncolix, Inc. is being awarded $2,400,000 Commercialization Award.

About Houston Technology Center

Named among Forbes' top 10 "incubators changing the world," The Houston Technology Center provides education, insight, and access to capital that entrepreneurs need for commercialization. The Houston Technology Center is a business accelerator and the largest technology business incubator in Texas, advancing the commercialization of emerging technology companies in the greater Houston area.  A 501(C)(3)nonprofit organization, HTC assists Houston-based entrepreneurs within several key sectors: energy, information technology, life sciences, nanotechnology and NASA/aerospace technologies.  For more information, visit www.houstontech.org.

About Gulf Coast RCICThe GCRCIC is responsible for processing applications for Commercial Awards from the Texas Emerging Technology Fund from individuals and companies, located within the Gulf Coast region.  The Gulf Coast RCIC researches each application and submits recommendations to the Emerging Technology Fund Advisory Committee.  The Gulf Coast RCIC assists with commercialization of the funded technologies, as well as provides private support to the companies and workforce.

Connect with us: twitter facebook LinkedinContact:Maggie JoplinDirector, Marketing and CommunicationsHouston Technology Center832-476-9235mjoplin@houstontech.org
'/>"/>

SOURCE Houston Technology Center
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
2. Open House at Gulf Coast Cancer Treatment Center Introduces Elekta Synergy® to Community
3. Health Care Organization Donates Funds to Gulf Coast Relief Organization
4. Hanley Center Acquires the East Coasts First SPECT Scanner to Treat Addiction
5. Inclement East Coast Weather Delays ProUroScan(TM) FDA Review
6. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
7. CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccinations Coast to Coast
8. Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
9. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
10. Congressional Sting Operation Uncovered By Coast IRB
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):